Technical Analysis for RIGL - Rigel Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 2.15 -1.83% -0.04
RIGL closed down 1.83 percent on Friday, May 17, 2019, on 1.28 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical RIGL trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Shooting Star Candlestick Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Doji - Bearish? Reversal 0.00%
Stochastic Reached Oversold Weakness 0.00%
Outside Day Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish -1.83%
Bollinger Band Squeeze Range Contraction -1.83%

Older signals for RIGL ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel and small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for the treatment of rheumatoid arthritis; R343, an inhaled SYK inhibitor that is in Phase II clinical trials to treat asthma; R333, a topical dermatological janus kinase (JAK)/SYK inhibitor, which is in Phase II clinical trials for the treatment of discoid lupus erythematosus; and R348, a topical ophthalmic JAK/SYK inhibitor that is in Phase I clinical trials to treat keratoconjunctivitis sicca. The company also conducts preclinical studies for an oral activator of adenosine monophosphate activated protein kinase to enhance the body's energy utilization and restore muscle endurance in chronically ill subjects. Rigel Pharmaceuticals, Inc. has collaboration agreements with AstraZeneca AB to develop and commercialize oral SYK inhibitors; and Daiichi Sankyo to conduct research related to drug targets called ligases that control cancer cell proliferation through protein degradation, as well as a license agreement with BerGenBio AS for the development and commercialization of an oncology program. The company was founded in 1996 and is based in South San Francisco, California.
Cancer Chemical Compounds Rheumatoid Arthritis Asthma Drug Development Enzymes Tyrosine Kinase Inhibitors Inflammatory And Autoimmune Diseases Tyrosine Kinase Janus Kinase Portola Pharmaceuticals Tyrosine Kinases
Is RIGL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.09
52 Week Low 1.96
Average Volume 1,463,776
200-Day Moving Average 2.6205
50-Day Moving Average 2.3666
20-Day Moving Average 2.254
10-Day Moving Average 2.228
Average True Range 0.1163
ADX 16.49
+DI 13.4509
-DI 17.0272
Chandelier Exit (Long, 3 ATRs ) 2.1411
Chandelier Exit (Short, 3 ATRs ) 2.4789
Upper Bollinger Band 2.3813
Lower Bollinger Band 2.1267
Percent B (%b) 0.09
BandWidth 11.295475
MACD Line -0.053
MACD Signal Line -0.0447
MACD Histogram -0.0083
Fundamentals Value
Market Cap 267.44 Million
Num Shares 124 Million
EPS -0.68
Price-to-Earnings (P/E) Ratio -3.16
Price-to-Sales 45.70
Price-to-Book 6.79
PEG Ratio -0.10
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.32
Resistance 3 (R3) 2.34 2.30 2.29
Resistance 2 (R2) 2.30 2.26 2.29 2.28
Resistance 1 (R1) 2.23 2.23 2.21 2.21 2.27
Pivot Point 2.19 2.19 2.18 2.18 2.19
Support 1 (S1) 2.11 2.14 2.09 2.09 2.03
Support 2 (S2) 2.07 2.11 2.06 2.02
Support 3 (S3) 2.00 2.07 2.01
Support 4 (S4) 1.98